Titlebook: Recombinant Antibodies for Cancer Therapy; Methods and Protocol Martin Welschof,Jürgen Krauss Book 2003 Humana Press 2003

從未迷惑

書目名稱Recombinant Antibodies for Cancer Therapy影響因子(影響力)




書目名稱Recombinant Antibodies for Cancer Therapy影響因子(影響力)學(xué)科排名




書目名稱Recombinant Antibodies for Cancer Therapy網(wǎng)絡(luò)公開度




書目名稱Recombinant Antibodies for Cancer Therapy網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Recombinant Antibodies for Cancer Therapy被引頻次




書目名稱Recombinant Antibodies for Cancer Therapy被引頻次學(xué)科排名




書目名稱Recombinant Antibodies for Cancer Therapy年度引用




書目名稱Recombinant Antibodies for Cancer Therapy年度引用學(xué)科排名




書目名稱Recombinant Antibodies for Cancer Therapy讀者反饋




書目名稱Recombinant Antibodies for Cancer Therapy讀者反饋學(xué)科排名

cancer

Generation of Antibody Molecules Through Antibody Engineeringances in the fields of cell biology and clinical diagnostics (.). However, in spite of their early promise, monoclonal antibodies (MAbs) were largely unsuccessful as therapeutic reagents resulting from insufficient activation of human effector functions and immune reactions against proteins of murin

Commodious

Application of Recombinant Antibodies in Cancer Patientsnical trials since the early 1980s. Clinical outcomes were generally poor (.–.), with the notable exception of marked tumor responses, including long-term remissions of patients with malignant B-cell lymphoma who were treated with patient-specific antiidiotypic antibodies (.–.). The main factors res

Pulmonary-Veins

DNA Immunization as a Means to Generate Antibodies to Proteins for a number of intractable diseases. Their uses include identification and cloning of new genes from expression libraries, purification and structure-function analysis of proteins, histochemical localization of proteins, as diagnostic markers and/or probes, as targeting agents to deliver drugs and

無孔

人類的發(fā)源

ICLE

幻影

Single-Domain VH Antibody Fragments from a Phage Display Libraryng any given molecular entity (antigen). Antigen recognition is conferred to the antibody by a limited number of hypervariable surface loops, differing in sequence and in length, which are connected to a conserved framework structure.

Customary

Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selectionchemotherapeutic agents for the treatment of ovarian cancer, survival is still poor. Major problems in ovarian cancer chemotherapies are a failure to consolidate response, acquired/intrinsic drug resistance, and dose-limiting toxicity. Thus new therapeutic treatment modalities have been developed, m

cornucopia